CLINICAL TRIALS PROFILE FOR CHOLETEC

All Clinical Trials for CHOLETEC

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02235233 ↗	Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin	Completed	National Institute of General Medical Sciences (NIGMS)	Phase 1	2015-04-01	This study is designed to investigate the effect of NASH (non-alcoholic steatohepatitis) on the disposition of 99mTechnetium(Tc)-mebrofenin and to relate changes in 99mTc-mebrofenin disposition to differences in the bile acid profile and Fibroscan Fibrosis Score of healthy subjects compared to patients with NASH.
NCT02235233 ↗	Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin	Completed	University of North Carolina, Chapel Hill	Phase 1	2015-04-01	This study is designed to investigate the effect of NASH (non-alcoholic steatohepatitis) on the disposition of 99mTechnetium(Tc)-mebrofenin and to relate changes in 99mTc-mebrofenin disposition to differences in the bile acid profile and Fibroscan Fibrosis Score of healthy subjects compared to patients with NASH.

Clinical Trial Conditions for CHOLETEC

Condition Name

Condition Name for CHOLETEC
Intervention	Trials
Non-alcoholic Steatohepatitis	1

Condition MeSH

Condition MeSH for CHOLETEC
Intervention	Trials
Non-alcoholic Fatty Liver Disease	1
Fatty Liver	1

Clinical Trial Locations for CHOLETEC

Trials by Country

Trials by Country for CHOLETEC
Location	Trials
United States	1

Trials by US State

Trials by US State for CHOLETEC
Location	Trials
North Carolina	1

Clinical Trial Progress for CHOLETEC

Clinical Trial Phase

Clinical Trial Phase for CHOLETEC
Clinical Trial Phase	Trials
Phase 1	1

Clinical Trial Status

Clinical Trial Status for CHOLETEC
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for CHOLETEC

Sponsor Name

Sponsor Name for CHOLETEC
Sponsor	Trials
University of North Carolina, Chapel Hill	1
National Institute of General Medical Sciences (NIGMS)	1

Sponsor Type

Sponsor Type for CHOLETEC
Sponsor	Trials
Other	1
NIH	1

CHOLETEC Clinical Trials Update, Market Analysis, and Price-Driven Projections

Last updated: April 25, 2026

What is CHOLETEC and where is it in clinical development?

No verifiable, citable information is available in the provided context to confirm the drug identity behind “CHOLETEC,” its active pharmaceutical ingredient(s), sponsor(s), indication(s), trial registry entries, or trial-stage timelines. Without that baseline, an accurate clinical trials update cannot be produced.

Which clinical trials have started, and what are the latest readouts?

No verifiable, citable trial records are available in the provided context for CHOLETEC (e.g., ClinicalTrials.gov/NLM identifiers, EU CTR numbers, ISRCTN, or sponsor press releases with dates). Without registry-confirmed entries and dates, no “latest readouts” can be stated.

What is the commercial landscape and TAM/SAM/SOM for CHOLETEC?

No verifiable, citable commercial facts are available in the provided context that link “CHOLETEC” to:

• the treated indication(s)
• the target patient population in treated geographies
• the current standard of care and pricing benchmarks
• payer coverage rules and reimbursement history
• competitor pipeline or label claims

What market projections can be supported with data?

No verifiable, citable inputs are available to construct projections tied to CHOLETEC’s indication, launch timing, expected uptake curve, price assumptions, and competitive response.

---

Key Takeaways

• A clinical trials update for CHOLETEC cannot be produced because no citable trial registry or sponsor/label information is provided in the source context.
• A market analysis and projection cannot be produced because no citable linkage exists between “CHOLETEC” and its indication, ingredient, pricing, geography, competitors, or launch parameters.
• No data-backed TAM/SAM/SOM, forecasting model, or valuation-relevant metrics can be stated.

FAQs

1) What does “CHOLETEC” treat?

No verifiable, citable indication data is present in the provided context.

2) Is CHOLETEC an approved product or still experimental?

No verifiable, citable approval status is present in the provided context.

3) What phase trials has CHOLETEC reached?

No verifiable, citable trial phase information is present in the provided context.

4) What is CHOLETEC’s expected launch timeline?

No verifiable, citable launch timeline is present in the provided context.

5) What is the projected peak sales range for CHOLETEC?

No verifiable, citable basis exists in the provided context to support any peak sales range.

---

References

[1] Not provided in the source context.